Spago Nanomedical AB (publ)

DB:7UX Stock Report

Market Cap: €8.2m

Spago Nanomedical Management

Management criteria checks 2/4

Spago Nanomedical's CEO is Mats Hansen, appointed in Jan 2015, has a tenure of 10.08 years. total yearly compensation is SEK2.40M, comprised of 72.3% salary and 27.7% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth €9.13K. The average tenure of the management team and the board of directors is 4.8 years and 1.8 years respectively.

Key information

Mats Hansen

Chief executive officer

SEK 2.4m

Total compensation

CEO salary percentage72.3%
CEO tenure10.1yrs
CEO ownership0.1%
Management average tenure4.8yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mats Hansen's remuneration changed compared to Spago Nanomedical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 34m

Jun 30 2024n/an/a

-SEK 33m

Mar 31 2024n/an/a

-SEK 34m

Dec 31 2023SEK 2mSEK 2m

-SEK 42m

Sep 30 2023n/an/a

-SEK 44m

Jun 30 2023n/an/a

-SEK 45m

Mar 31 2023n/an/a

-SEK 45m

Dec 31 2022SEK 2mSEK 2m

-SEK 39m

Sep 30 2022n/an/a

-SEK 39m

Jun 30 2022n/an/a

-SEK 41m

Mar 31 2022n/an/a

-SEK 43m

Dec 31 2021SEK 2mSEK 1m

-SEK 39m

Sep 30 2021n/an/a

-SEK 32m

Jun 30 2021n/an/a

-SEK 27m

Mar 31 2021n/an/a

-SEK 20m

Dec 31 2020SEK 2mSEK 1m

-SEK 19m

Sep 30 2020n/an/a

-SEK 20m

Jun 30 2020n/an/a

-SEK 21m

Mar 31 2020n/an/a

-SEK 21m

Dec 31 2019SEK 2mSEK 1m

-SEK 20m

Sep 30 2019n/an/a

-SEK 18m

Jun 30 2019n/an/a

-SEK 15m

Mar 31 2019n/an/a

-SEK 13m

Dec 31 2018SEK 1mSEK 1m

-SEK 11m

Compensation vs Market: Mats's total compensation ($USD220.47K) is below average for companies of similar size in the German market ($USD463.54K).

Compensation vs Earnings: Mats's compensation has increased whilst the company is unprofitable.

CEO

Mats Hansen (53 yo)

10.1yrs

Tenure

SEK 2,401,000

Compensation

Dr. Mats Hansen, MSc., PhD, serves as the Chief Executive Officer of Spago Nanomedical AB (publ) since 2015. Dr. Hansen has experience from different companies in the life science industry. He served at A...

Leadership Team

NamePositionTenureCompensationOwnership
Mats Hansen
Chief Executive Officer10.1yrsSEK 2.40m0.11%
€ 9.1k
Hanna Olsson
Chief Financial Officer6.1yrsno data0.019%
€ 1.6k
Oskar Axelsson
Head of Research & Chief Scientific Officerno datano data0.048%
€ 4.0k
Paul Hargreaves
Chief Development Officer3.4yrsno data0.017%
€ 1.4k
Birgitta Svensson
Head of CMC & Supplyless than a yearno datano data

4.8yrs

Average Tenure

53yo

Average Age

Experienced Management: 7UX's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hans Arwidsson
Independent Chairman of the Board1.8yrsSEK 200.00k0.14%
€ 11.8k
Sten Nilsson
Medical Advisor1.8yrsSEK 32.00kno data
Alan Raffensperger
Independent Director1.8yrsSEK 100.00k0.23%
€ 19.2k
Kari Gronas
Independent Director7.1yrsSEK 132.00k0.057%
€ 4.7k
Per Hall
Medical Advisor2.7yrsno datano data
Nicklas Westerholm
Independent Director5.5yrsSEK 132.00k0.021%
€ 1.7k
Timothy Roberts
Medical Advisor2.7yrsno datano data
Kristian Pietras
Medical Advisor1.8yrsno datano data
Austin Smith
Medical Advisor1.7yrsno datano data

1.8yrs

Average Tenure

64yo

Average Age

Experienced Board: 7UX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 18:06
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Spago Nanomedical AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Klas PalinPenser Access
Johan UnnerusRedeye